Advertisement
Singapore markets close in 5 hours 10 minutes

  • Straits Times Index

    3,276.74
    -11.01 (-0.33%)
     

  • Nikkei

    37,926.06
    +297.58 (+0.79%)
     

  • Hang Seng

    17,587.69
    +303.15 (+1.75%)
     

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • Bitcoin USD

    64,396.60
    +14.67 (+0.02%)
     

  • CMC Crypto 200

    1,390.72
    +8.15 (+0.59%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,345.00
    +2.50 (+0.11%)
     

  • Crude Oil

    83.79
    +0.22 (+0.26%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,572.20
    +2.95 (+0.19%)
     

  • Jakarta Composite Index

    7,112.26
    -43.04 (-0.60%)
     

  • PSE Index

    6,555.74
    -19.14 (-0.29%)
     

Top Ranked Momentum Stocks to Buy for April 3rd

Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd:

electroCore, Inc. (ECOR): This bioelectronic medicine company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 48.7% over the last 60 days.

electroCore, Inc. Price and Consensus

electroCore, Inc. Price and Consensus
electroCore, Inc. Price and Consensus

electroCore, Inc. price-consensus-chart | electroCore, Inc. Quote

electroCore’s shares gained 5.1% over the last one month above the S&P 500’s decrease of 12.8%. The company possesses a Momentum Score of A.

electroCore, Inc. Price

electroCore, Inc. Price
electroCore, Inc. Price

electroCore, Inc. price | electroCore, Inc. Quote

ADVERTISEMENT

CytomX Therapeutics, Inc. (CTMX): This oncology-focused biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.2% over the last 60 days.

CytomX Therapeutics, Inc. Price and Consensus

CytomX Therapeutics, Inc. Price and Consensus
CytomX Therapeutics, Inc. Price and Consensus

CytomX Therapeutics, Inc. price-consensus-chart | CytomX Therapeutics, Inc. Quote

CytomX Therapeutics’ shares gained 4.2% over the last one month. The company possesses a Momentum Score of A.

CytomX Therapeutics, Inc. Price

CytomX Therapeutics, Inc. Price
CytomX Therapeutics, Inc. Price

CytomX Therapeutics, Inc. price | CytomX Therapeutics, Inc. Quote

DHT Holdings, Inc. (DHT): This crude oil tankers operator has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 41.6% over the last 60 days.

DHT Holdings, Inc. Price and Consensus

DHT Holdings, Inc. Price and Consensus
DHT Holdings, Inc. Price and Consensus

DHT Holdings, Inc. price-consensus-chart | DHT Holdings, Inc. Quote

DHT’s shares gained 35% over the last one month. The company possesses a Momentum Score of A.

DHT Holdings, Inc. Price

DHT Holdings, Inc. Price
DHT Holdings, Inc. Price

DHT Holdings, Inc. price | DHT Holdings, Inc. Quote

Aytu BioScience, Inc. (AYTU): This specialty pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.8% over the last 60 days.

Aytu Bioscience, Inc. Price and Consensus

Aytu Bioscience, Inc. Price and Consensus
Aytu Bioscience, Inc. Price and Consensus

Aytu Bioscience, Inc. price-consensus-chart | Aytu Bioscience, Inc. Quote

Aytu BioScience’s shares gained more than 100% over the last one month. The company possesses a Momentum Score of A.

Aytu Bioscience, Inc. Price

Aytu Bioscience, Inc. Price
Aytu Bioscience, Inc. Price

Aytu Bioscience, Inc. price | Aytu Bioscience, Inc. Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.   

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>                                 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
electroCore, Inc. (ECOR) : Free Stock Analysis Report
 
DHT Holdings, Inc. (DHT) : Free Stock Analysis Report
 
CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report
 
Aytu Bioscience, Inc. (AYTU) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research